Taiwan
· Delayed Price · Currency is TWD Bora Pharmaceuticals Co., LTD. Statistics
Total Valuation
Bora Pharmaceuticals Co., LTD. has a market cap or net worth of TWD 77.38 billion. The enterprise value is 91.23 billion.
| Market Cap | 77.38B |
| Enterprise Value | 91.23B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | Aug 12, 2024 |
Share Statistics
Bora Pharmaceuticals Co., LTD. has 100.75 million shares outstanding. The number of shares has increased by 4.35% in one year.
| Shares Outstanding | 100.75M |
| Shares Change (YoY) | +4.35% |
| Shares Change (QoQ) | -0.32% |
| Owned by Insiders (%) | 8.22% |
| Owned by Institutions (%) | 11.34% |
| Float | 56.56M |
Valuation Ratios
The trailing PE ratio is 25.14 and the forward PE ratio is 17.68.
| PE Ratio | 25.14 |
| Forward PE | 17.68 |
| PS Ratio | 5.48 |
| PB Ratio | 8.08 |
| P/FCF Ratio | 121.49 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.34, with an EV/FCF ratio of 143.25.
| EV / Earnings | 28.63 |
| EV / Sales | 6.44 |
| EV / EBITDA | 19.34 |
| EV / EBIT | 22.87 |
| EV / FCF | 143.25 |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 150.28.
| Current Ratio | 1.19 |
| Quick Ratio | 0.89 |
| Debt / Equity | 150.28 |
| Debt / EBITDA | 3.94 |
| Debt / FCF | 29.22 |
| Interest Coverage | 15.65 |
Financial Efficiency
Return on equity (ROE) is 33.98% and return on invested capital (ROIC) is 11.20%.
| Return on Equity (ROE) | 33.98% |
| Return on Assets (ROA) | 7.78% |
| Return on Capital (ROIC) | 11.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.44 |
| Inventory Turnover | 2.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 802.24 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 51.82 |
| Average Volume (20 Days) | 1,815,686 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bora Pharmaceuticals Co., LTD. had revenue of TWD 14.17 billion and earned 3.19 billion in profits. Earnings per share was 30.55.
| Revenue | 14.17B |
| Gross Profit | 6.80B |
| Operating Income | 3.99B |
| Pretax Income | 4.10B |
| Net Income | 3.19B |
| EBITDA | 4.62B |
| EBIT | 3.99B |
| Earnings Per Share (EPS) | 30.55 |
Balance Sheet
The company has 7.56 billion in cash and 18.61 billion in debt, giving a net cash position of -11.05 billion or -109.67 per share.
| Cash & Cash Equivalents | 7.56B |
| Total Debt | 18.61B |
| Net Cash | -11.05B |
| Net Cash Per Share | -109.67 |
| Equity (Book Value) | 12.38B |
| Book Value Per Share | 95.05 |
| Working Capital | 3.96B |
Cash Flow
In the last 12 months, operating cash flow was 1.01 billion and capital expenditures -374.14 million, giving a free cash flow of 636.88 million.
| Operating Cash Flow | 1.01B |
| Capital Expenditures | -374.14M |
| Free Cash Flow | 636.88M |
| FCF Per Share | 6.32 |
Margins
Gross margin is 47.99%, with operating and profit margins of 28.16% and 22.50%.
| Gross Margin | 47.99% |
| Operating Margin | 28.16% |
| Pretax Margin | 28.93% |
| Profit Margin | 22.50% |
| EBITDA Margin | 32.64% |
| EBIT Margin | 28.16% |
| FCF Margin | 4.50% |
Dividends & Yields
This stock pays an annual dividend of 12.00, which amounts to a dividend yield of 1.57%.
| Dividend Per Share | 12.00 |
| Dividend Yield | 1.57% |
| Dividend Growth (YoY) | 94.84% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 19.43% |
| Buyback Yield | -4.35% |
| Shareholder Yield | -2.78% |
| Earnings Yield | 3.98% |
| FCF Yield | 0.82% |
Stock Splits
The last stock split was on August 10, 2023. It was a forward split with a ratio of 1.2989035.
| Last Split Date | Aug 10, 2023 |
| Split Type | Forward |
| Split Ratio | 1.2989035 |